In vitro diagnostics specialist bioMérieux has announced a 21% drop in net income (group share) to 358 million euros for 2023, but operating income of 610 million euros (or 16.6% of sales), up 2% on an organic basis.

At 3.67 billion euros, sales were up 6.6% on an organic basis, 'thanks to an excellent performance by Biofire's microbiology and non-breathing panel sales, and to a lower-than-expected decline in Biofire's breathing panel sales'.

At the Annual General Meeting on May 23, the Board of Directors will propose a stable dividend of 0.85 euros per share for the past year, representing a payout ratio of 28% of net income, higher than usual.

For 2024, bioMérieux expects, at constant exchange rates and scope of consolidation, an increase in operating income before non-recurring items of at least 10%, and sales growth of between 6 and 8%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.